午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜,COLO 205
  • COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜,COLO 205

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

價(jià)格 詢價(jià)
包裝 1000000細(xì)胞數(shù) 2000000細(xì)胞數(shù)
最小起訂量 1000000細(xì)胞數(shù)
發(fā)貨地 上海
更新日期 2025-07-24
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜英文名稱:COLO 205
品牌: ATCC\RCB等產(chǎn)地: 國(guó)外
保存條件: 常溫培養(yǎng)或液氮凍存純度規(guī)格: COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜
產(chǎn)品類別: 化學(xué)試劑
種屬: 詳見(jiàn)產(chǎn)品資料組織: 詳見(jiàn)產(chǎn)品資料
細(xì)胞系: 詳見(jiàn)產(chǎn)品資料細(xì)胞形態(tài): 詳見(jiàn)產(chǎn)品資料
生長(zhǎng)狀態(tài): 詳見(jiàn)產(chǎn)品資料靶點(diǎn): 詳見(jiàn)產(chǎn)品資料
應(yīng)用: 詳見(jiàn)產(chǎn)品資料
2025-07-24 COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜 COLO 205 1000000細(xì)胞數(shù)/RMB;2000000細(xì)胞數(shù)/RMB ATCC\RCB等 國(guó)外 常溫培養(yǎng)或液氮凍存 COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜 化學(xué)試劑

"COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例:1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性:貼壁生長(zhǎng)

【細(xì)胞培養(yǎng)經(jīng)驗(yàn)分享】啟蒙老師的重要性:一般進(jìn)實(shí)驗(yàn)室都有師兄師姐帶著做,他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則,如營(yíng)養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開(kāi)蓋手法、細(xì)胞吹打手法等等。要學(xué)會(huì)他們的正確操作,在第一次的時(shí)候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞,細(xì)胞有時(shí)真的很脆弱,最好每天都去看看它,以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異常現(xiàn)象,也好及時(shí)解決這些意外,避免重復(fù)實(shí)驗(yàn)帶來(lái)的更大痛苦。好細(xì)胞要及時(shí)保種:細(xì)胞要分批傳代,這樣即使有一批出了問(wèn)題,還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn),有一次細(xì)胞污染了,全軍覆沒(méi)。當(dāng)時(shí)可后悔沒(méi)有保種。細(xì)胞跟人一樣,不同的細(xì)胞,培養(yǎng)特性是不一樣的。培養(yǎng)過(guò)程中要細(xì)細(xì)體會(huì),不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期:每周2-3次

H2081 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:隨細(xì)胞的密度而增加;生長(zhǎng)特性:懸浮生長(zhǎng);形態(tài)特性:聚團(tuán)懸浮;相關(guān)產(chǎn)品有:hFOB細(xì)胞、NCI-H2171細(xì)胞、CP70細(xì)胞

TCC-SUP Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代,2-3天換液1次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:NTERA-2/D1細(xì)胞、COLO824細(xì)胞、SK-RC-20細(xì)胞

HEK-2 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HCC0366細(xì)胞、SUM-102細(xì)胞、Namalva細(xì)胞

背景信息:該細(xì)胞系是1957年由T.U.Sle等從患有結(jié)腸癌的70歲男性白人的腹水中分離的。該病人在取腹水樣前已用5-尿嘧啶治療4~6周。角蛋白免疫過(guò)氧化物酶染色陽(yáng)性;產(chǎn)生A、IL10。

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝:復(fù)蘇發(fā)貨:T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨:1ml凍存管(兩支)

DSMZ菌株保藏中心成立于1969年,是德國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、質(zhì)粒、抗菌素、人體和動(dòng)物細(xì)胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心,保藏有動(dòng)物細(xì)胞500多株。Riken BRC成立于1920年,是英國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細(xì)胞系。在世界范圍內(nèi),這些細(xì)胞系,都在醫(yī)學(xué)、科學(xué)和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學(xué)術(shù)、健康、食品和獸醫(yī)機(jī)構(gòu)的研究工作,并在世界各地不同組織的微生物實(shí)驗(yàn)室和研究機(jī)構(gòu)中使用。

KYSE-140 Cells;背景說(shuō)明:食管鱗癌細(xì)胞;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MDA-MB-453細(xì)胞、PCI-SG231細(xì)胞、BV-2細(xì)胞

T241 Cells;背景說(shuō)明:纖維肉瘤;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:JeKo 1細(xì)胞、VMCUB1細(xì)胞、MRC5細(xì)胞

Hs 27 Cells;背景說(shuō)明:包皮;成纖維細(xì)胞;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:TE-13細(xì)胞、A101D細(xì)胞、HEP-3B2細(xì)胞

1E7 [Mouse hybridoma against human IL1-activated endothelial cells] Cells(提供STR鑒定圖譜)

來(lái)源說(shuō)明:細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

物種來(lái)源:人源、鼠源等其它物種來(lái)源

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性:上皮細(xì)胞樣

貼壁消化難題:1,先用PBS 把細(xì)胞洗兩遍,使瓶?jī)?nèi)沒(méi)有血清了,減少對(duì)胰酶的中和,然后用新配的0.25%的胰酶加入3ml左右,放在37度,然后可以在細(xì)胞有些消化下來(lái)時(shí),拿著瓶口,運(yùn)用手腕的力量輕輕震蕩瓶?jī)?nèi)體,這樣細(xì)胞很快就下來(lái)了,還不需要吹打,分散也均勻;2,成團(tuán)、絮狀:消化里加入eda可以減少細(xì)胞成團(tuán)的現(xiàn)象,血清可以終止胰酶的作用,如果是進(jìn)口血清的話也能終止eda的作用。用胰酶消化后胰酶可以倒掉,也可以不倒,直接加血清終止,如果消化中加入了eda的話,就要將消化倒干凈,如果細(xì)胞貼壁要求不是很嚴(yán)格的話,一般不需要進(jìn)行離心。鼻咽癌細(xì)胞的貼壁能力很強(qiáng),用0.5%胰酶(含0.1%EDA)一般要消化12~15min。用PBS洗滌時(shí)要洗凈殘余的培養(yǎng)基,加入胰酶后在培養(yǎng)箱中消化(避免細(xì)胞室溫下受損以及在此溫度時(shí)胰酶活性Zui強(qiáng))至細(xì)胞收縮變圓(可顯微鏡下觀察)且有少許細(xì)胞脫落(有流下來(lái)的趨勢(shì)),隨后立即棄去胰酶(如果脫落的細(xì)胞很多且需要大量細(xì)胞實(shí)驗(yàn),則不能棄去胰酶),加入培養(yǎng)基仔細(xì)吹打(不能用無(wú)血清培養(yǎng)基或者PBS替代,否則細(xì)胞聚集成團(tuán)塊或絮狀)。一般我都離心一次棄去上清(去除殘留的胰酶及漂浮的死細(xì)胞或細(xì)胞碎片);消化過(guò)度:馬上用培養(yǎng)基中和,用吸管吹打細(xì)胞,收集全部的細(xì)胞到以無(wú)菌的離心管中800RPM 3分鐘。棄上清,用全培重懸,換新的培養(yǎng)瓶繼續(xù)培養(yǎng),狀態(tài)不HAO的細(xì)胞在培養(yǎng)的過(guò)程中會(huì)死亡脫落,在換的時(shí)候可以清除掉!

CC-LP-I Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MES-SA Dx5細(xì)胞、NCIH2052細(xì)胞、OVHM細(xì)胞

A7r5 Cells;背景說(shuō)明:培養(yǎng)到穩(wěn)定期后細(xì)胞表現(xiàn)出長(zhǎng)高的肌激酶和肌酸激酶活性(CPK)。 細(xì)胞分裂終止后合成骨肉型CPK。;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:成纖維細(xì)胞;相關(guān)產(chǎn)品有:SKCol1細(xì)胞、HuH6細(xì)胞、NCI-H64細(xì)胞

Panc5.04 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:Hs281T細(xì)胞、H2342細(xì)胞、TOV21細(xì)胞

MGH-UI Cells;背景說(shuō)明:膀胱癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:ASH3細(xì)胞、Bovine Turbinate細(xì)胞、SK-MEL3細(xì)胞

JROECL 33 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:HOCF細(xì)胞、BHK細(xì)胞、C3H10T1/2CL8細(xì)胞

Caki-2 Cells;背景說(shuō)明:該細(xì)胞源自一位69歲白人男性的初期腎腺癌組織;傳代方法:1:3—1:6傳代,每周換液2—3次;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:SK-Mel 1細(xì)胞、B16-F10-BL6細(xì)胞、MPVECs細(xì)胞

MCF-7B Cells;背景說(shuō)明:浸潤(rùn)性導(dǎo)管癌;胸腔積液轉(zhuǎn)移;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Jurkat E6.1細(xì)胞、TFK-1細(xì)胞、NCIH1703細(xì)胞

TE6 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:MEF細(xì)胞、Hs 274.T細(xì)胞、DLM8細(xì)胞

NCI-H847 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Namalwa細(xì)胞、NCI-H-128細(xì)胞、IPLB-SF 21AE細(xì)胞

CEMC1 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng) ;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:DK-MG細(xì)胞、H9c2 (2-1)細(xì)胞、MDCK.2細(xì)胞

UCLA RO-81A-1 Cells;背景說(shuō)明:甲狀腺癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Stanford University-Diffuse Histiocytic Lymphoma-2細(xì)胞、Hep3B細(xì)胞、M14-MEL細(xì)胞

CII Cells;背景說(shuō)明:慢性淋巴細(xì)胞白血??;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MLFC細(xì)胞、bEnd3細(xì)胞、HEL92.1.7細(xì)胞

MESSA Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:6-1:8?jìng)鞔?;每周?3次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:成纖維細(xì)胞樣 ;相關(guān)產(chǎn)品有:M109細(xì)胞、KYSE-70細(xì)胞、L1210細(xì)胞

HSF Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:成纖維細(xì)胞樣;相關(guān)產(chǎn)品有:C3H10T1/2 clone8細(xì)胞、MGECs細(xì)胞、NCIH2106細(xì)胞

H-295 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:RDES-1細(xì)胞、LOU-NH91細(xì)胞、T-cell Acute Lymphoblastic Leukemia-1細(xì)胞

JVM3 Cells;背景說(shuō)明:慢性髓白血?。慌?傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:NCI-SNU-761細(xì)胞、MDA-MB-231細(xì)胞、SH-SY5Y細(xì)胞

MDCK II Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:3傳代,3-4天傳1次;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:SC1細(xì)胞、G-292細(xì)胞、130 T細(xì)胞

13C1 Cells(提供STR鑒定圖譜)

Abcam HeLa FLYWCH1 KO Cells(提供STR鑒定圖譜)

AG21241 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRF214 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XG429 Cells(提供STR鑒定圖譜)

C0182 Cells(提供STR鑒定圖譜)

CW60051 Cells(提供STR鑒定圖譜)

DA05473 Cells(提供STR鑒定圖譜)

Genomeditech CHO-K1 H_CB1 Cells(提供STR鑒定圖譜)

KLN-205 Cells;背景說(shuō)明:肺;鱗癌細(xì)胞;DBA;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:RCS細(xì)胞、H1437細(xì)胞、Centre Antoine Lacassagne-51細(xì)胞

CAL-27 Cells;背景說(shuō)明:該細(xì)胞1982年由J. Gioanni建系,源自一位56歲白人男性的舌頭中倍的病變部位,角蛋白強(qiáng)陽(yáng)性;傳代方法:1:6傳代,2—3天換液一次;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:CAL-51細(xì)胞、My-La 2059細(xì)胞、NCI-747細(xì)胞

HMEL Cells;背景說(shuō)明:上皮細(xì)胞;永生化;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Strain V細(xì)胞、HEK 293A細(xì)胞、H1184細(xì)胞

HL-60 clone15 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:維持細(xì)胞濃度在1×105-1×106/ml,每2-3天換液1次。;生長(zhǎng)特性:懸浮生長(zhǎng);形態(tài)特性:淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有:MLOY4細(xì)胞、Tn-5B1-4細(xì)胞、NIH-OVCAR-3細(xì)胞

NCI-H1793 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:3-1:6傳代 ;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:Sol8細(xì)胞、Colo-678細(xì)胞、H-2135細(xì)胞

SK MEL-28 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:3-1:8?jìng)鞔?,?3天換液1次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:星形的;相關(guān)產(chǎn)品有:Mv 1 Lu細(xì)胞、SK-ChA1細(xì)胞、RGCs細(xì)胞

FRH-0201 Cells;背景說(shuō)明:膽管癌;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:LNCaP-Clone-FGC細(xì)胞、H-125細(xì)胞、SCLC-21H細(xì)胞

NCI-H1299 Cells;背景說(shuō)明:這株細(xì)胞來(lái)源于一個(gè)淋巴結(jié)轉(zhuǎn)移?;颊呓邮芰顺跗诜暖?。細(xì)胞均一性的部分缺失p53蛋白,并缺少p53蛋白表達(dá)。細(xì)胞可以合成0.1pmol/毫克蛋白的NMB蛋白,而不合成促胃液釋放肽(GRP)。;傳代方法:1:2傳代;3天傳代一次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;多角形;相關(guān)產(chǎn)品有:COR-L23細(xì)胞、Madison 109細(xì)胞、C643細(xì)胞

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

PNT1/A Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HCC-1599細(xì)胞、Hs729T細(xì)胞、NRK-49F細(xì)胞

TE4 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:RKO_AS45細(xì)胞、SNB-19細(xì)胞、BrCL18細(xì)胞

HUVSMC Cells;背景說(shuō)明:臍靜脈平滑肌;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:H1436細(xì)胞、H2081細(xì)胞、SKMEL-1細(xì)胞

DLD1 Cells;背景說(shuō)明:DLD-1是1977-1979年間D.L.Dexter和同事分離的兩株結(jié)直腸腺癌細(xì)胞株中的一株。在ATCC和其它地方進(jìn)行的DNAfingerprinting和染色體組型分析表明這株細(xì)胞與HCT-15(CCL-225)相似,說(shuō)明這兩者是來(lái)自同一個(gè)人的不同克隆。他們的遺傳起源可通過(guò)DNAfingerprinting證實(shí),但染色體組型分析顯示它們?nèi)狈θ旧w標(biāo)記一致改變或數(shù)目上一致改變。細(xì)胞的CSAp陰性(CSAp-)。DLD-1細(xì)胞的p53抗原表達(dá)呈陽(yáng)性(p53抗原產(chǎn)生了一個(gè)C->;傳代方法:消化5分鐘。1:2。4-5天長(zhǎng)滿。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:AgC11x3A細(xì)胞、Roswell Park Memorial Institute 1846細(xì)胞、Mahlavu細(xì)胞

HLF Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:成纖維細(xì)胞樣;相關(guān)產(chǎn)品有:HSC-T6細(xì)胞、NCI-H774細(xì)胞、SW-1222細(xì)胞

SK-MEL-31 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:4-1:6傳代,2-3天換液1次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:CHO cell clone K1細(xì)胞、Centre Antoine Lacassagne-39細(xì)胞、PC 61.5.3細(xì)胞

G-401 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:6傳代,每周2-3次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:NCIH889細(xì)胞、OC316細(xì)胞、Asian Medical Center-Head and Neck cancer-8細(xì)胞

GM18876 Cells(提供STR鑒定圖譜)

HAP1 IGF2BP3 (-) 4 Cells(提供STR鑒定圖譜)

16-HBEo Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng) ;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Normal Rat Kidney-49F細(xì)胞、OSC-19細(xì)胞、NCIH1915細(xì)胞

EOMA Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:P3/NSI/1-AG4-1細(xì)胞、OB2細(xì)胞、H-548細(xì)胞

TMK1 Cells;背景說(shuō)明:胃癌;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HMEC細(xì)胞、NCIH1819細(xì)胞、RSC-96細(xì)胞

IHC-ST1 Cells;背景說(shuō)明:肝內(nèi)膽管癌;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Be-Wo細(xì)胞、H-3255細(xì)胞、HPC-Y5細(xì)胞

293 EBNA Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:4-1:10傳代;每周2次。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:Calu 3細(xì)胞、SUM159細(xì)胞、B 95-8細(xì)胞

WEHI 164 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HFLS-OA細(xì)胞、H-250細(xì)胞、Neuro-2a細(xì)胞

Murine Long bone Osteocyte-Y4 Cells;背景說(shuō)明:骨;SV40轉(zhuǎn)化;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SCC VII細(xì)胞、OCI/AML5細(xì)胞、MONO-MAC 6細(xì)胞

3T6-Swiss albino Cells;背景說(shuō)明:胚胎;成纖維;自發(fā)永生;雄性;Swiss albino;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:PC-9/S1細(xì)胞、STC-1細(xì)胞、G361細(xì)胞

HPS0388 Cells(提供STR鑒定圖譜)

JJ0055 Cells(提供STR鑒定圖譜)

MDA-MB-461 Cells(提供STR鑒定圖譜)

ND38554 Cells(提供STR鑒定圖譜)

PS 4-15 Cells(提供STR鑒定圖譜)

Ubigene Hep G2 ZNF133 KO Cells(提供STR鑒定圖譜)

Y-79 Eto-R Cells(提供STR鑒定圖譜)

HG01858 Cells(提供STR鑒定圖譜)

C918 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng) ;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:BNL CL.2細(xì)胞、HCT-15細(xì)胞、MDA435細(xì)胞

KYSE450 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:NALM 6細(xì)胞、HEK293FT細(xì)胞、KMBC細(xì)胞

Panc-813 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:IA-LM細(xì)胞、PCI:SG-231細(xì)胞、OE-19細(xì)胞

Human Corneal Epithelial cells-Transformed Cells;背景說(shuō)明:角膜上皮細(xì)胞;Ad-SV40轉(zhuǎn)化;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:NCIH1755細(xì)胞、NCI H69細(xì)胞、WEHI-3B細(xì)胞

MHHCALL2 Cells;背景說(shuō)明:急性B淋巴細(xì)胞白血?。慌?傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SK-MEL-24細(xì)胞、Mouse Forestomach Carcinoma細(xì)胞、WM35細(xì)胞

MHHCALL2 Cells;背景說(shuō)明:急性B淋巴細(xì)胞白血病;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SK-MEL-24細(xì)胞、Mouse Forestomach Carcinoma細(xì)胞、WM35細(xì)胞

OVCAR-4 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:WML2細(xì)胞、MBT2細(xì)胞、H-2591細(xì)胞

KMBC Cells;背景說(shuō)明:膽管癌;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MKN-28細(xì)胞、TE 85 ClF-5細(xì)胞、Neukoplast細(xì)胞

AC16 [Human hybrid] Cells;背景說(shuō)明:心肌;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SU86.86細(xì)胞、L2細(xì)胞、L23/P細(xì)胞

L-Wnt-3A Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MC3T3-E細(xì)胞、A-172細(xì)胞、RPMI-1788細(xì)胞

MiaPaCa-2 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:TW-039細(xì)胞、FET細(xì)胞、Potorous tridactylus Kidney 1細(xì)胞

MILE SVEN 1 Cells;背景說(shuō)明:MS1是1994年建株的胰島內(nèi)皮細(xì)胞株。原代培養(yǎng)的胰島內(nèi)皮細(xì)胞用抗G418的溫度敏感型SV40大T抗原(tsA-58-3)轉(zhuǎn)染??剐钥寺∮每寺…h(huán)分離,并篩選吸收dil-Ac-LDL的。這株細(xì)胞保留了內(nèi)皮細(xì)胞的許多特性,如吸收乙?;疞DL和表達(dá)八因子相關(guān)抗原及BEGF受體。;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:AN3 CA細(xì)胞、Ha Fe細(xì)胞、GM04154細(xì)胞

Ly10 Cells;背景說(shuō)明:彌漫大B細(xì)胞淋巴瘤;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SK-LU-1細(xì)胞、NRK 52E細(xì)胞、HT 144細(xì)胞

DHL4 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:懸浮;形態(tài)特性:淋巴母細(xì)胞;相關(guān)產(chǎn)品有:IALM細(xì)胞、CALU 1細(xì)胞、GDM1細(xì)胞

HNTEC Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:MES-SA細(xì)胞、NRK clone 52E細(xì)胞、MCM細(xì)胞

SLR20 Cells(提供STR鑒定圖譜)

NCIH2141 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:3-4天換液1次。;生長(zhǎng)特性:懸浮生長(zhǎng);形態(tài)特性:聚團(tuán)懸浮;相關(guān)產(chǎn)品有:Large Cell Lung Cancer-103H細(xì)胞、BJAB-1細(xì)胞、MESSA-DX5細(xì)胞

BIC Cells;背景說(shuō)明:食管腺癌;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:NCI-H1563細(xì)胞、Adeno 293細(xì)胞、Panc-3_27細(xì)胞

NCIH1703 Cells;背景說(shuō)明:該細(xì)胞1987年建系,源自一位54歲患有非小細(xì)胞肺癌的白人男性,該患者為吸煙者。;傳代方法:1:3—1:6傳代,每周換液2—3次;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:NK-10A細(xì)胞、Hs 683細(xì)胞、A-172MG細(xì)胞

SJRH 30 Cells;背景說(shuō)明:肺泡橫紋肌肉瘤;骨髓轉(zhuǎn)移;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:NCI-H498細(xì)胞、GA-10(Clone 4)細(xì)胞、HVSMC細(xì)胞

mREC Cells;背景說(shuō)明:視網(wǎng)膜;內(nèi)皮 Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SKNBE(2c)細(xì)胞、16-HBE14o細(xì)胞、LLC-PK-1細(xì)胞

alpha-TC1-6 Cells;背景說(shuō)明:胰島素瘤;a細(xì)胞;C57BL/6xDBA/2;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:SW-527細(xì)胞、CTV-1細(xì)胞、SLK細(xì)胞

TE5 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:MN-9D細(xì)胞、NCI-H2066細(xì)胞、TE-5細(xì)胞

KYSE-270 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:5傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:MCA 38細(xì)胞、NCI-H2108細(xì)胞、GM02132C細(xì)胞

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜

C-127 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁或懸浮,詳見(jiàn)產(chǎn)品說(shuō)明書部分;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:McARH7777細(xì)胞、TOV112細(xì)胞、BPH-1細(xì)胞

HSCT6 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:LSECs細(xì)胞、NCI-HUT-460細(xì)胞、GLAG-66細(xì)胞

H-2452 Cells;背景說(shuō)明:詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性:貼壁生長(zhǎng);形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:S-16細(xì)胞、RM-1細(xì)胞、MC3T3-E細(xì)胞

CCD-841CoN Cells;背景說(shuō)明:結(jié)腸上皮細(xì)胞;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HPF細(xì)胞、MC-4細(xì)胞、GM02131A細(xì)胞

F442A Cells;背景說(shuō)明:脂肪前體細(xì)胞;雄性;Swiss albino;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:HT 115細(xì)胞、NOK細(xì)胞、H2228細(xì)胞

NCI-H128 Cells;背景說(shuō)明:小細(xì)胞肺癌;胸腔積液轉(zhuǎn)移;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長(zhǎng)特性:貼壁;形態(tài)特性:詳見(jiàn)產(chǎn)品說(shuō)明書;相關(guān)產(chǎn)品有:Panc-05.04細(xì)胞、H-2052細(xì)胞、MDCK supertube細(xì)胞

BayGenomics ES cell line RRR311 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHD276 Cells(提供STR鑒定圖譜)

hTf26-9B Cells(提供STR鑒定圖譜)

PCRP-HOMEZ-1B5 Cells(提供STR鑒定圖譜)

F2408 EBNA2 cl-28 Cells(提供STR鑒定圖譜)

HPS3099 Cells(提供STR鑒定圖譜)

" "PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)


PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)


PubMed=7651727

Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Oncogene 11:647-652(1995)


PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)


PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)


PubMed=10051639; DOI=10.1073/pnas.96.5.2316; PMCID=PMC26781

Efstathiou J.A., Liu D., Wheeler J.M.D., Kim H.C., Beck N.E., Ilyas M., Karayiannakis A.J., Mortensen N.J., Kmiot W.A.W., Playford R.J., Pignatelli M., Bodmer W.F.

Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells.

Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999)


PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3

Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.

Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.

Eur. J. Cancer 35:1724-1729(1999)


PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)


PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)


PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)


PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)


PubMed=12584437; DOI=10.1159/000068544

Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R., Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M., Koehrle J., Al-Taie O.

Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway.

Cytogenet. Genome Res. 98:22-28(2002)


PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)


PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)


PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)


PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)


PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)


PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)


PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)


PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)


PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)


PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)


PubMed=23272949; DOI=10.1186/1755-8794-5-66; PMCID=PMC3543849

Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

BMC Med. Genomics 5:66.1-66.15(2012)


PubMed=23631600; DOI=10.1021/pr400260h

Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.

Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.

J. Proteome Res. 12:2980-2986(2013)


PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)


PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)


PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)


PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)


PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)


PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)


PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)


PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019

Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.

Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.

J. Proteomics 127:247-258(2015)


PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)


PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)


PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)


PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)


PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)


PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)


PubMed=28192450; DOI=10.1371/journal.pone.0171435; PMCID=PMC5305277

Fasterius E., Raso C., Kennedy S.A., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.

A novel RNA sequencing data analysis method for cell line authentication.

PLoS ONE 12:E0171435-E0171435(2017)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)


PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Mol. Cancer 16:116.1-116.16(2017)


PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)


PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165; PMCID=PMC6670293

Clark D.J., Hu Y.-W., Bocik W., Chen L.-J., Schnaubelt M., Roberts R.R., Shah P., Whiteley G.R., Zhang H.

Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.

J. Proteome Res. 17:2205-2215(2018)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)


PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)"



關(guān)鍵字: COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已;傳代細(xì)胞;復(fù)蘇細(xì)胞;實(shí)驗(yàn)細(xì)胞;科研細(xì)胞;

公司簡(jiǎn)介

上海冠導(dǎo)生物工程有限公司,先后從ATCC、DSMZ、ECACC、RIKEN、PromoCell、ScienCell、JCRB等國(guó)內(nèi)外細(xì)胞庫(kù)引進(jìn)細(xì)胞2000余株。以此為契機(jī),公司組建了冠導(dǎo)細(xì)胞庫(kù),我司細(xì)胞均由資深細(xì)胞培養(yǎng)工程師進(jìn)行培養(yǎng)。我司可以提供的細(xì)胞有:①細(xì)胞系②原代細(xì)胞③穩(wěn)轉(zhuǎn)株④耐藥株⑤標(biāo)記細(xì)胞⑥細(xì)胞配套試劑等。
成立日期 2015-11-05 (10年) 注冊(cè)資本 100萬(wàn)(元)
員工人數(shù) 50-100人 年?duì)I業(yè)額 ¥ 1000萬(wàn)-5000萬(wàn)
主營(yíng)行業(yè) 細(xì)胞培養(yǎng),微生物學(xué),細(xì)胞生物學(xué) 經(jīng)營(yíng)模式 工廠,試劑,定制,服務(wù)
  • 上海冠導(dǎo)生物工程有限公司
VIP 5年
  • 公司成立:10年
  • 注冊(cè)資本:100萬(wàn)(元)
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:①細(xì)胞系②原代細(xì)胞③穩(wěn)轉(zhuǎn)株④耐藥株⑤標(biāo)記細(xì)胞⑥細(xì)胞配套試劑等。
  • 公司地址:手機(jī)號(hào)/微信號(hào):18818239863 【QQ號(hào):3171921642】上海市張江高科技園區(qū)
詢盤

COLO 205人結(jié)腸癌細(xì)胞全年復(fù)蘇|已有STR圖譜相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
VIP1年
上海賓穗生物科技有限公司
2025-07-24
詢價(jià)
VIP7年
上海弘順生物科技有限公司
2025-07-24
詢價(jià)
VIP6年
上海賓穗生物科技有限公司
2025-07-24
¥1500
VIP4年
上海雅吉生物科技有限公司
2025-07-24
¥1500
VIP3年
上海滬震實(shí)業(yè)有限公司
2025-07-23
¥1799
VIP1年
上海鈺博生物科技有限公司
2025-06-15
詢價(jià)
VIP1年
上海賓穗生物科技有限公司
2025-07-24
詢價(jià)
VIP6年
上海賓穗生物科技有限公司
2025-07-24
¥1800
VIP4年
上海雅吉生物科技有限公司
2025-07-24
詢價(jià)
VIP1年
上海賓穗生物科技有限公司
2025-07-24
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè) | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.